MorphoSys AG (NASDAQ:MOR) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET
Company Participants
Julia Neugebauer - Vice President, Head of Investor Relations
Jean-Paul Kress - Chief Executive Officer
Tim Demuth - Chief Research and Development Officer
Joe Horvat - General Manager MorphoSys US
Conference Call Participants
Jason Butler - JMP Securities
James Quigley - Morgan Stanley
Zain Ebrahim - JPMorgan
Vineet Agrawal - Citi
Operator
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the First Quarter Interim Statement 2023 of MorphoSys. Throughout today's recorded call, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to Julia Neugebauer. Please go ahead.
Julia Neugebauer
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys and it is my pleasure to welcome you to our first quarter 2023 financial results conference call.
Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Tim Demuth, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager, who will join for the Q&A.
Before we begin, I'd like to remind you on slide two that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans, and expectations for the compounds in our pipeline as well as the development plans of our collaboration partners.
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys' 20-F and annual report, all for the year ended December 31st, 2022, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements in this webcast speak as of today.
On slide three, you will find the agenda for today's call. Jean-Paul will begin with an overview and the outlook. After that, Tim will share an update on our clinical development work and then we will provide a summary of our first quarter 2023 financial results. Following our prepared remarks, we will open the call for your questions.
With that, I now hand the call over to Jean-Paul.
Jean-Paul Kress
Good morning, and good afternoon, everyone. Thanks for joining us today. We had a strong first quarter marked by numerous achievements. We are more focused than ever on the opportunities ahead of us this year and I'm confident that we will deliver.